FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Conditions
Ovarian Cancer · Non-small Cell Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The University of Alabama, Birmingham, Alabama, United States
Mount Sinai, New York, New York, United States
Christ Hospital, Cincinnati, Ohio, United States
Contact: Study coordinator (Christ Hospital Research Center) · ct-inquiries@tubulis.com · +1 972-893-8800Ohio State University, Columbus, Ohio, United States
OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Next Oncology Dallas, Irving, Texas, United States
Next Oncology Virginia, Fairfax, Virginia, United States
UZ Leuven, Leuven, Belgium, Belgium
Charité Universitätsmedizin Berlin, Berlin, Germany
Contact: Study coordinator (Charité Universitätsmedizin Berlin Research Center) · ct-inquiries@tubulis.comUniversity Hospital Cologne Department of Internal Medicine I, Cologne, Germany
Arensia Exploratory Medicine, Cluj-Napoca, Romania
Clínica universidad de Navarra, Madrid, Spain
Contact: Study coordinator (Clínica universidad de Navarra Research Center) · ct-inquiries@tubulis.comNEXT Oncology Madrid, Madrid, Spain
Arensia Exploratory Medicine, Kyiv, Ukraine
Guy's Hospital, London, United Kingdom
Study leads
Yariv Houvras, MD, PhD
Study Director
Tubulis GmbH